ArticleImmunity, inflammation and disease2026
Cyanobacterium Brasilonema sp. LPS Induces Neutrophil Infiltration and Lung Inflammation in a TLR4-Dependent Manner and Exacerbates Th2-Dependent Lung Inflammation.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundChronic airway inflammation can be induced by both chemical and environmental factors. Airway inflammation can be induced through different immune pathways, including allergic Th2-dependent activation of eosinophils and mast cells, Th1/Th17-dependent neutrophil recruitment, or a combination of both mast cell and neutrophil recruitment, that is extremely difficult to treat. An environmental factor that we have shown to induce neutrophil-mediated lung inflammation is cyanobacterium lipopolysaccharide (LPS). The study has two main objectives: first to determine whether TLR4 is required for cyanobacterium LPS-induced lung inflammation, given our prior findings that it signals differently from other LPS types, and second to test if cyanobacterium LPS exacerbates lung inflammation in a Th2-dependent mouse model of airway hypersensitivity.
methodsLPS from the cyanobacterium strain, Brasilonema sp., was purified and used for both in vivo and in vitro assays. For in vitro assays, the TLR4 inhibitor, SPA-4, was assessed in its ability to block Brasilonema sp.-dependent IL-6 and IL-8 induction in lung epithelial cell lines, and in vivo, the ability of Brasilonema sp. LPS to induce lung inflammation was assessed in TLR4-deficient mice in comparison to controls. Finally, Th2-driven lung inflammation was established using ovalbumin and then these mice were exposed to Brasilonema sp. LPS intranasally to assess if Brasilonema sp. LPS resulted in the exacerbation of Th2-dependent airway inflammation.
resultsOur results indicate that Brasilonema sp. LPS stimulates the production of cytokines both in vitro and in vivo in a TLR4-dependent manner, since the addition of the SPA-4 peptide blocks Brasilonema sp. LPS-dependent increases in IL-6 and IL-8 in vitro and TLR4-deficient mice were refractory to Brasilonema sp. LPS-mediated induction of lung inflammation in vivo. Additionally, both E. coli and Brasilonema sp. LPS exacerbated airway inflammation in a Th2-dependent model of lung inflammation. However, Brasilonema sp. LPS exacerbated Th2-dependent lung inflammation without significant neutrophil infiltration.
conclusionsDespite the altered signaling through TLR4 by cyanobacterium LPS, these data demonstrate that lung inflammation induced by LPS from the cyanobacterium strain, Brasilonema sp., requires TLR4 and exacerbates Th2-dependent lung inflammation. Therefore, novel interventions that target TLR4 may be beneficial in the treatment of LPS-induced lung inflammation from environmental exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.